Mortality in a heterogeneous population of low-risk febrile neutropenic patients treated initially with cefazolin and tobramycin

摘要

BACKGROUND:At Sunnybrook Health Sciences Centre in Toronto, Ontario, the recommended empiric regimen for febrile neutropenia has been cefazolin and tobramycin for at least 25 years. However, we had no objective data to reassure us that patient mortality had not increased over the past five years.